{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:50:38Z","timestamp":1763560238546,"version":"3.45.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"International University of Health and Welfare Research Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12328-025-02223-x","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:39:20Z","timestamp":1758883160000},"page":"1144-1148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Remarkable response to durvalumab and tremelimumab in a patient with hepatocellular carcinoma: a case report"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-1009","authenticated-orcid":false,"given":"Yosuke","family":"Osawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Akita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"2223_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.185.3.393","volume":"185","author":"PA van der Merwe","year":"1997","unstructured":"van der Merwe PA, Bodian DL, Daenke S, et al. CD80 (B7\u20131) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med. 1997;185:393\u2013403.","journal-title":"J Exp Med"},{"key":"2223_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","volume":"1","author":"PS Linsley","year":"1994","unstructured":"Linsley PS, Greene JL, Brady W, et al. Human B7\u20131 (CD80) and B7\u20132 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1:793\u2013801.","journal-title":"Immunity"},{"key":"2223_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40364-023-00535-z","volume":"12","author":"N Zhang","year":"2024","unstructured":"Zhang N, Yang X, Piao M, et al. Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. Biomark Res. 2024;12:26.","journal-title":"Biomark Res"},{"key":"2223_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101554","author":"Z Macek Jilkova","year":"2019","unstructured":"Macek Jilkova Z, Aspord C, Decaens T. Predictive factors for response to PD-1\/PD-L1 checkpoint inhibition in the field of hepatocellular carcinoma: current status and challenges. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11101554.","journal-title":"Cancers (Basel)"},{"key":"2223_CR5","first-page":"29","volume":"97","author":"G Fiore","year":"1999","unstructured":"Fiore G, Piazzolla G, Galetta V, et al. Liver tissue expression of CD80 and CD95 antigens in chronic hepatitis C: relationship with biological and histological disease activities. Microbios. 1999;97:29\u201338.","journal-title":"Microbios"},{"key":"2223_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/hep.510250337","volume":"25","author":"K Mochizuki","year":"1997","unstructured":"Mochizuki K, Hayashi N, Katayama K, et al. B7\/BB-1 expression and hepatitis activity in liver tissues of patients with chronic hepatitis C. Hepatology. 1997;25:713\u20138.","journal-title":"Hepatology"},{"key":"2223_CR7","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/hep.510250511","volume":"25","author":"T Tatsumi","year":"1997","unstructured":"Tatsumi T, Takehara T, Katayama K, et al. Expression of costimulatory molecules B7\u20131 (CD80) and B7\u20132 (CD86) on human hepatocellular carcinoma. Hepatology (Baltimore, MD). 1997;25:1108\u201314.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"2223_CR8","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/j.1440-1746.2004.03467.x","volume":"19","author":"K Fujiwara","year":"2004","unstructured":"Fujiwara K, Higashi T, Nouso K, et al. Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2004;19:1121\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"2223_CR9","first-page":"435","volume":"12","author":"RC Chan","year":"2004","unstructured":"Chan RC, Xie Y. CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens. Oncol Rep. 2004;12:435\u201342.","journal-title":"Oncol Rep"},{"key":"2223_CR10","doi-asserted-by":"publisher","first-page":"1496992","DOI":"10.3389\/fimmu.2024.1496992","volume":"15","author":"L Li","year":"2024","unstructured":"Li L, Yang L, Jiang D. Research progress of CD80 in the development of immunotherapy drugs. Front Immunol. 2024;15:1496992.","journal-title":"Front Immunol"},{"key":"2223_CR11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","volume":"51","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Lee CK, Lin CH, et al. PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways. Immunity. 2019;51:1059-73.e9.","journal-title":"Immunity"},{"key":"2223_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920928635","volume":"12","author":"D Bianconi","year":"2020","unstructured":"Bianconi D, Herac M, Posch F, et al. Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. Ther Adv Med Oncol. 2020;12:1758835920928635.","journal-title":"Ther Adv Med Oncol"},{"key":"2223_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx066","author":"C Bais","year":"2017","unstructured":"Bais C, Mueller B, Brady MF, et al. Tumor microvessel density as a potential predictive marker for Bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst. 2017. https:\/\/doi.org\/10.1093\/jnci\/djx066.","journal-title":"J Natl Cancer Inst"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02223-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-025-02223-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02223-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:46:36Z","timestamp":1763559996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-025-02223-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2223"],"URL":"https:\/\/doi.org\/10.1007\/s12328-025-02223-x","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest in relation to this work","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}